Life Sciences Archive » November, 2019

Life Sciences - November, 2019

258 articles

• NY Appeals Court Rules Against McDermott In Privilege Row
• Insys Verdict Flip Is A Check On Aggressive Feds
• Allergan Hid Breast Implants' Cancer Risk, Women Say
• Teva Slips FCA Suit, Giving DOJ Another Granston Memo Win
• Fed. Circ. Tosses Sleep Mask PTAB Appeal Over Standing
• Coherus, Amgen End Patent War Over Humira Biosimilar
• Where BPCIA Issues Stand As FDA Approves 25th Biosimilar
• Nelson Mullins Nabs 2 IP Attorneys From Mintz
• Tracking 3 Enforcement Trends In Health Care
• Headaches Abound As States Try To Clarify CBD Landscape
• Schools Poised To Open New Front In Opioid MDL
• Brown Rudnick Accused Of Bungling $300M Bankruptcy Claim
• Boston Heart Settles FCA Suit Over Referral Fraud For $26.7M
• True Health's Ch. 11 Plan Confirmed Despite CMS' Protests
• Insys Judge Drops Part Of Landmark Opioid Verdict
• Janssen Can't Use Tenn. Law To Nix $70M Risperdal Verdict
• AbbVie Says AndroGel Suit Should Be Moved To Georgia
• NYC Council Approves Bill To Ban Flavored E-Cigs
• Ex-MiMedx Execs Charged With Cooking Biotech Co.'s Books
• Full Fed. Circ. Won't Rehear ITC E. Coli Patent Row
• Bayer Essure Injury Suits Kicked Back To Pa. State Court
• Weitz & Luxenberg Beats Ex-Client's Appeal Over BMS Case
• FDA Won't Vouch For CBD's Safety In Products
• Fed. Circ. Undoes 'Cryptic' PTAB Ruling In Pfizer Vaccine Row
• Merck Hits Generic Co. With IP Suit Over Diabetes Drug
• Baxter Hit With Stock Drop Suit Over Forex Accounting
• Roche Hit With $137M Verdict For Infringing Lab Test Patents
• Humira Buyers Say They've Proven AbbVie's 'Patent Thicket'
• Boston Scientific Gets Sanctions Nixed In FCA Suit
• CVS Customers Certify NY, Ariz. Classes In Generic Price Suit
• Takeda Wants Immediate Appeal Of Actos Order 'Uncertainty'
• Implant Co.'s Insurer Can Recoup Costs, Nev. Justices Told
• Fla. High Court Won't Hear Challenge To Pot-Growing Ban
• Book Review: Who's To Blame For The Broken Legal System?
• Justices Decline Pfizer's LA Court Fight, Hospital FCA Cases
• 3rd Circ. Sends Fosamax Suits To District Court
• Ferring, Blackstone Ink $570M Bladder Cancer Therapy Deal
• Supreme Court Has 'No Work' To Do On Mayo, Clinic Says
• SEC Expands Ad Fraud Suit Against Outcome Health Execs
• ​​​​​​​​​​​​​​Paul Weiss, S&C Shape $9.7B Novartis Deal For NJ Drugmaker
• IP Firm Faces $10M Malpractice Suit Over Denied Gene Patent
• California Revokes Cannabis Co.'s Licenses After Raid
• Pa. Appeals Court To Rethink J&J's $20M Mesh Verdict Appeal
• Fed. Circ. Backs J&J Unit's Win In Glucose Test Strip IP Suit
• Calif. Pot Markup Will Rise On New Year's Day, Tax Dept. Says
• New Deal Anchors AndroGel Antitrust Suit To Pa., Buyers Say
• Advising Cannabis Cos. As Mich. Legalizes Recreational Use
• How States' 2020 Policy Agendas Are Taking Shape
• The Top Pennsylvania Employment Law Changes In 2019
• J&J Loses 'Premature' Bid To Toss $37.3M Asbestos Verdict
• UK Litigation Roundup: Here's What You Missed In London
• Health Hires: Ropes & Gray, Arnold & Porter
• Dykema Taps Corporate Finance Atty For Chicago Office
• HHS Attys Say High Court Ruling Curbs Billing Enforcement
• Monsanto Can't Ditch LA County's PCB Suit
• Teva Gets PTAB To Review Cushing's Syndrome Drug Patent
• USDA Hemp Rules Pose Problems, Oregon Sens. Say
• Democratic Candidates Advocate For Busting Drug Patents
• Insys Reaches Creditor Deal For Tiered Ch. 11 Recoveries
• PTAB Probes Authenticity Of Prior Art In Pain Treatment Case
• Pharma Co. Wins $16.7M At Trial Over Inflated Ad Costs
• Deals Rumor Mill: Hudson's Bay, Charles Schwab, DoorDash
• House Advances Bills Targeting Pharma IP Practices
• Fed. Circ. Ruling May Affect Eligibility Of Life Sciences Patents
• Disclosure, Transparency Regs Headline DOL Benefits Agenda
• Harvest Health Walks Away From $225M Financing Deal
• Zimmer Must Face Pa. Woman's Faulty Hip Implant Claims
• AbbVie Investors Fight Bid To Toss Humira Kickbacks Suit
• Fund Pays $4M To Settle Mass. Medicare Kickback Probe
• Buyers Chide Endo's Claim That Class Too Small For Cert. Bid
• Hologic Inks $205M Sale Of 'Underperforming' Med Tech Co.
• Senators Press FDA Nominee On Vaping Flavor Ban
• Pa. Justices Reopen Time For 'Thousands' Of Risperdal Suits
• Cancer Treatment Startup Raises $56M In Funding
• House Panel Approves Cannabis Tax, Decriminalization Bill
• House Committee Advances Sweeping Pot Legalization Bill
• Gov. Can't Ban Vapes Via Exec Order, Mass. Top Court Hears
• Urine Maker Owes $900K In Atty Fees After Loss In IP Suit
• Opioid MDL Judge Plots New Bellwether Trials Across US
• Mass. Gov. Defends Vape Ban In 'Time Of Crisis'
• Purdue Gets OK To Pay States' Costs In Opioid-Related Ch. 11
• Direct Buyers Seek Cert. In Zetia Generic Delay Suit
• Full Fed. Circ. Won't Look At Patents For Withholding Meds
• True Health Ch. 11 Plan Draws Feds' Fire Over CMS Claims
• Fed. Circ. Upholds Mylan's PTAB Win On Insulin Drug Lantus
• GreenVision Targets Health Care Acquisition After $50M IPO
• No Full Fed. Circ. Review In Genzyme Cancer Patent Case
• Colo. Judge Skips SEC Insider Trading Deposition
• Health Care Fraud Lessons For Lawyers Advising Doctors
• How To Hire Lateral Partners More Effectively
• Lumenis Nabs $1B Value In Sale To Baring PE Asia
• Lawyers Can Counsel Medical Pot Clients, NY Bar Says
• Jury To Hash Out Insurers' $10M Lightning Strike Claim Row
• GNC Broke Deal With Supplement Maker, Pa. Judge Says
• Retrial Sought Against J&J After FDA Finds Asbestos In Talc
• Roche Says Biotech Co. Wants To Stretch Tech Royalty Rights
• Purdue Opioid Claims Need National Fix, High Court Told
• Calif. AG Sues Juul Over Advertising To Teens
• Wellington Nabs $393M To Invest In Novel Drug Developers
• Judge Caps Insys Exec's 'Astronomical' Nixon Peabody Tab
• US Trustee Says Sackler Ties Bar E&Y From Purdue Ch. 11
• J&J Defeats New Trial Bid In NJ Asbestos-In-Talc Case
• MVP: Cohen Milstein's Sharon K. Robertson
• Supreme Court Won't Hear Martin Shkreli's Appeal
• FTC Clears Bristol-Myers' $74B Celgene Buy With Drug Sale
• RJR, Phillip Morris Owe $157M To Smoker's Widow, Jury Says
• Recently Reversed: How J&J, Avis & LG Toppled Big Verdicts
• Texas Justices To Weigh Reach Of Forum Choice In Deals
• J&J's $572M Opioid Loss Cut To $465M As Judge Fixes Math
• Motley Rice's Joseph Rice On The Opioid MDL And More
• Indivior Can't Duck Opioid Marketing Fraud Indictment
• Oregon Court Blocks State Ban On Flavored Cannabis Vapes
• Purdue Says Paying States' Costs Will Help Ch. 11 Estate
• Opioid Distributors Didn't Cause Nuisance, Pa. Judge Told
• 5 Takeaways As DOJ Finds Footing In FCA Dismissal Crusade
• Retailers Can Split Claims In Loestrin Antitrust Trial
• CBD Retailer Says Dosage Suit Doesn't Show Actual Injury
• FDA Rules For CBD Supplements Urgently Needed, Org Says
• MVP: Steptoe & Johnson's John Molenda
• The Coming Storm Of Biometric Privacy Laws: How To Comply
• Perrigo Investors Win Cert. In Suit Over Thwarted Sale
• Cannabis Lobby Grows As Congress Mellows Out On Pot
• Massachusetts Supreme Court Keeps Vape Ban In Place
• Senators Float Bill To Create Drug-Pricing Agency
• Hospira Infringed 2 Valid Par Adrenalin Patents, Judge Says
• Roche Inks Up To $1.39B Deal For Goodwin-Advised Biotech
• CBD Capsule Case Belongs In State Court, Plaintiff Says
• Insys Alters Ch. 11 Plan After Claimant Deal Falls Through
• Health Care Ad Co. Ex-Executive Faces Fraud Claims
• Mass. Biotech Co. Sues Feds Over Denial Of Visa For Scientist
• 9th Circ. Judge Calls DOJ's Appeal In FCA Suit 'A Mistake'
• Calif. Panel Revives Allergan Worker's Mistaken Firing Suit
• CBD Product Maker Can Refile Libel Suit Against Writer
• Rare HHS Patent Suit May Impact HIV Drug Pricing, Access
• Deals Rumor Mill: Xerox, Thyssenkrupp, Thermo Scientific
• The Coming Storm Of Biometric Privacy Laws: What To Expect
• Retrieval-Masters To Share Data Breach Info With State AGs
• Engaging With International Carcinogen Evaluations
• Michigan Moves Up Recreational Pot Sales To Dec. 1
• MVP: Gibson Dunn's Jane M. Love
• Purdue's Law Firms Must Return Retainers, US Trustee Says
• Galena Again Beats Investors' 'Shotgun' Opioid Claims Suit
• GSK Says Boehringer Spreading Lies About Its Inhalers
• Drug Cos. May Rethink Patent Strategy After Fed. Circ. Ruling
• HHS Beats Suit Over Radioactive Drugs In Medicaid Program
• 3rd Circ. Slams J&J Bid To Out HIV Drug Suit Whistleblowers
• Purdue Claimants Oppose Payment Of Settling States' Costs
• Ex-Immunomedics Brass Must Face Del. Suit Over $250M Deal
• Drugmakers Rip HHS At DC Circ. For Price-Disclosure Rule
• Women Sue Co. Over 'Exorbitantly Priced' Preterm Birth Drug
• MVP: Weil Gotshal's Edward Reines
• Covington Guides Merck In $576M Deal For Life Science Biz
• UBiome Trustee Seeks To Unload Assets By Mid-December
• Cancer Pharma Co. Dodges Investor Stock-Drop Suit
• Ex-Judge Wants Grand Jury Info On Rockefeller U. Sex Abuser
• Texas Could Take Page From Mass.'s Judicial Selection Book
• 7th Circ. Ends Insurer's RICO Suit In Testosterone MDL
• Spinal Implant Maker Files Ch. 11 Over Development Debt
• A Possible USPTO Solution To PTAB Constitutionality Ruling
• Hemp Industry Warns USDA Its THC Test Plans Are Impossible
• Wholesale Deals Can't Nix J&J Antitrust Row, 3rd Circ. Told
• Jones Day Picks Up Ex-SDNY Fraud Unit Co-Chief In NY
• FDA's Special Treatment Of Big Tech Faces Mounting Scrutiny
• Genetic Testing Gold Rush Gives Rise To Fraud Allegations
• Revised USPTO Trial Practice Guide Leans Pro-Patent Owners
• Kirkland Helps SK Capital Clinch PE Fund With $400M In Tow
• Judging A Book: McKeown Reviews 'Conversations With RBG'
• Legislative Trends May Kill Texas Employer Cannabis Tests
• Opioid Co. Inks $1.6M Deal To End Suit Over FDA Rejection
• MVP: Venable's Christopher P. Borello
• Mass. Pot Board Largely Preserves State Ban On Weed Vapes
• Law360 MVP Awards Go To Top Attorneys From 76 Firms
• Pradaxa User's Labeling Claims Preempted, Calif. Judge Rules
• E-Cig Co. Must Face Youth Marketing Suit In State Court
• DC Circ. Asks If HHS Had Leeway For Drug Payment Cuts
• Medical Pot Vapers Ask Mass. High Court To Let Ban Lapse
• CDC Finds Vitamin E Link To Vaping Lung Illnesses
• Dr. Reddy's Can't Kill Arthritis Drug Patent Suit Yet
• Utah Agrees To Drop Partial Ban On Flavored Vapes
• Noteworthy Changes From FDA's Latest Software Guidance
• Chinese Startups, US Biotechs Price IPOs Raising $121M
• 5 Things Cannabis Biz Attorneys Should Know About Tax Law
• Citizen Petitions Are Crucial In Managing A Drug's Life Cycle
• Taxation With Representation: Shearman, Skadden, Pillsbury
• Full Fed. Circ. Won't Rehear Venue Dispute In UT Patent Case
• States' Vaping Bans Face Legal Hurdles
• Sparks Fly In Opioid MDL As Judge, Attys Debate Next Trials
• NY AG's Trial Against Opioid Makers Scheduled For January
• Fed. Circ. Weighs Bid To Finish Off Pfizer Vaccine Patent
• Biogen Owes $6M For Firing Over FCA Reporting, Sex Bias
• Pot Cos. Ask 10th Circ. To Weigh Tax Case In Summons Row
• Pharma Supplier Inks $22M Deal With DOJ Over Inflated Prices
• Insurer Fights Claims Over Cryotherapy Injury Coverage
• Developments In State Taxation Of Nonadmitted Insurance
• Achillion Investor Seeks To Halt $930M Pharma Tie-Up
• Juul Pulls Mint Flavor From Market
• Gene Editing Co. Nabs $100M From Private Investors
• Calif. Privacy Law Compliance Strategies For Health Care Cos.
• Biotech Firms, Crypto Bank Raise $156M In Low-Pricing IPOs
• All Work, No Pay: HHS Sues Gilead Over HIV-Prevention IP
• Biopharma Firm Urges Chancery To Ax Cholesterol Drug Suit
• Rhode Island Flavored Vape Ban Will Stay In Effect For Now
• No Class Cert. Redo For ADHD Drug Buyers In Antitrust Suit
• Novartis Unit's Supplement Loaded With Aluminum, Suit Says
• 23AndMe Urges Full Fed. Circ. To Rethink DNA Patent Ruling
• Fed. Circ. Takes Issue With Hospira's 11th-Hour Arguments
• Purdue Opioid Suits Put On Hold Until April
• Wolf Haldenstein Tapped To Lead Curaleaf Stock Drop Suit
• Abbott Scores Win In Ex-Researcher's Retaliation Suit
• FTC Orders Prosthetic Maker To Unwind Merger
• Feds Ordered To Hand Over Docs To Ex-Theranos CEO
• Insys Creditors Say Liquidation Would Spark Chaos
• Where A Litigator's Advice Can Improve Agreement Drafting
• Industrial Hemp Could Save American Agriculture
• VC Firm Launches CA$200M Pool For Life Science Cos.
• Opioid MDL Judge Draws Fresh Fire From Pharmacies
• High Court Urged To Review Ruling Killing 2 Vimovo Patents
• Justices Should Allow Time-Bar Ruling Appeals, Biotech Says
• Mass. Board To Decide If Vape Ban Applies To Medical Pot
• Supplement Maker Hid Illegal Stimulant, Consumers Say
• Coloplast Sets Aside $60M For Surgical Mesh Litigation Costs
• Cannabis-Focused Blank Check Co. Prices Upsized $120M IPO
• M&A 'Pure Omission' Claims Test Limits Of Securities Laws
• 2nd Circ. Won't Revive Antitrust Suit Over Cancer Drugs
• New Calif. Pay-For-Delay Law May Hurt Those It Aims To Help
• Fed. Circ. Offers Obviousness-Type Double Patenting Cure
• Ex-Theranos CEO Claims FDA Destroyed Key Evidence
• Ballot Measure Can't Legalize Pot, Fla. Legislators Say
• Insys Ch. 11 Disclosures Draw Fire From DOJ, US Trustee
• ITC To Investigate Medical Device Imports
• Arthrex Seeks 2nd PTAB Redo After Constitutionality Ruling
• Mass. Top Court To Hear Argument Over State's Vaping Ban
• Imerys Asks For $1.3M To Motivate Workers During Ch. 11
• How To Drop A Client Ignoring Your Bills: 3 Cases To Know
• Supreme Court Passes On TWC Appeal, 4 Other Patent Cases
• Care.com Wants Investors' Background Check Suit Tossed
• Adapting To FDA's Proposal For Diagnosis Support Software
• Flat-Fee Legal Billing Can Liberate Attorneys
• 15 Minutes With Bausch Health's General Counsel
• 2 Firms Grab Lion's Share Of IPOs In Shaky October
• Skadden Guides Stryker's $4B Deal For Wright Medical
• Surveying The Fallout From The PTAB Constitutionality Ruling
• Ex-Fed. Circ. Judge Decries 'Fundamental Rift' Over Eligibility
• Warren Medicare Plan May Downplay Economic Impact Of Tax
• 16 Firms To Steer 9 IPOs Led By Canadian Co.'s $1.9B Offering
• Insys MDL Group Slams Del. Ch. 11 Doc As Fatally Flawed
• Fla. Fentanyl Dealer Sentenced To 30 Years Behind Bars
• Pa. Doctor To Pay $1.4M To Settle Opioid Prescription Claims
• Indiana Asks 7th Circ. To Reconsider 'Smokable Hemp' Ban
• Seroquel XR Suits Belong In Delaware, AstraZeneca Says
• Praxair Says Recent Ruling Won't 'Devastate' Medical Patents
• Spoliation Rule Remains Ambiguous Despite Amendments
• Deals Rumor Mill: Saudi Aramco, Bitmain, Alibaba
• Assessing USDA Hemp Rule's Impact On Cannabis IP
• Calif. Court Revives Veeva's Push To Void Noncompetes
• Trump Taps Cancer Doc To Lead FDA
• Health Hires: King & Spalding, Arnold & Porter
• Warren Wants Cos., The Rich To Pay For $20.5T Medicare Plan